drugset / Trial / NCT05697510
Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM
NaSequentialOpen-labelTreatment
Summary
This is a phase 1 dose escalation study testing the addition of an anti-IL6 (siltuximab) to standard induction chemotherapy for high-risk AML.
Timeline
- Start
- 2023-03-16
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 7 mg/kg | — |
| Subject | Siltuximab | Monoclonal antibody | 9 mg/kg | — |
| Subject | Siltuximab | Monoclonal antibody | 11 mg/kg | — |